ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2

ISSN 印刷: 0893-9675
ISSN オンライン: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v7.i3-4.20
pages 151-190

Antisense Regulation of Oncogenes in Human Cancer

Tapas Mukhopadhyay
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center
Jack A. Roth
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

要約

Gene transfer or manipulation of genes for the treatment of cancer is a rapidly expanding field. In recent years, much attention has been focused on manipulating cancer genes and applying antisense technology in therapeutic ways. Consequently, antisense RNA control is now recognized as a specific means of regulating gene expression at the posttranscriptional level. Defects in vital genes occur in many human diseases, including cancer, defects that may be due to an accumulation of mutations in the genes that leads to the production of faulty proteins. Although the biological significance of such mutant proteins still remains in question, recent experiments have demonstrated that genes overproducing faulty proteins are often associated with increased tumor cell growth. Moreover, using a stretch of antisense RNA to block the production of such defective proteins can effectively silence their genes; as a result, tumor cells stop dividing rapidly and revert to a more normal phenotype. Therefore, antisense RNA technology could have a significant impact on cancer gene therapy. Here, we have tried to give comprehensive coverage to some major cases of antisense RNA control of cancer-related genes highlighting the biological systems involved, the efficacy of the antisense RNA in altering target gene function, and how such antisense control affects the malignant phenotype. Furthermore, the therapeutic potential of the antisense technique depends on the in-depth understanding of the target gene function and its role in carcinogenesis.


Articles with similar content:

Histone Acetyltransferases in Cancer: Guardians or Hazards?
Critical Reviews™ in Oncogenesis, Vol.22, 2017, issue 3-4
Antonis Kirmizis, Christina Demetriadou
A New Linkage between the Tumor Suppressor RKIP and Autophagy: Targeted Therapeutics
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 5-6
Yuhao Wang, Benjamin Bonavida
Targeting MicroRNAs: Promising Future Therapeutics in the Treatment of Allergic Airway Disease
Critical Reviews™ in Eukaryotic Gene Expression, Vol.28, 2018, issue 2
Nicole G. Hansbro, Kamal Dua, Philip M. Hansbro, Paul S. Foster
Functional Role of MicroRNAs in Prostate Cancer and Therapeutic Opportunities
Critical Reviews™ in Oncogenesis, Vol.18, 2013, issue 4
Marcello Maugeri-Sacca, Valeria Coppola, Ruggero De Maria, Desiree Bonci
Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada